Total Payments
$1.3M
2024 Payments
$93,548
Companies
49
Transactions
1,818
Medicare Patients
12,392
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$1.1M (84.8%)
Travel$139,452 (11.0%)
Food & Beverage$43,405 (3.4%)
Consulting$10,281 (0.8%)
Education$378.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 413 | 84.8% |
| Travel and Lodging | $139,452 | 212 | 11.0% |
| Food and Beverage | $43,405 | 1,168 | 3.4% |
| Consulting Fee | $10,281 | 8 | 0.8% |
| Education | $378.34 | 16 | 0.0% |
| Debt forgiveness | $16.95 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $491,022 | 517 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $281,646 | 230 | $0 (2024) |
| Esperion Therapeutics, Inc. | $200,078 | 194 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $172,703 | 228 | $0 (2024) |
| Lilly USA, LLC | $115,632 | 120 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,446 | 66 | $0 (2024) |
| Amgen Inc. | $1,435 | 98 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,011 | 56 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $739.92 | 45 | $0 (2023) |
| Medtronic, Inc. | $695.71 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93,548 | 176 | Boehringer Ingelheim Pharmaceuticals, Inc. ($41,729) |
| 2023 | $86,485 | 163 | Boehringer Ingelheim Pharmaceuticals, Inc. ($50,494) |
| 2022 | $206,839 | 273 | Janssen Pharmaceuticals, Inc ($83,037) |
| 2021 | $156,990 | 185 | Esperion Therapeutics, Inc. ($79,992) |
| 2020 | $94,597 | 140 | Esperion Therapeutics, Inc. ($30,164) |
| 2019 | $228,322 | 275 | Janssen Pharmaceuticals, Inc ($104,331) |
| 2018 | $210,758 | 299 | Janssen Pharmaceuticals, Inc ($100,874) |
| 2017 | $194,626 | 307 | Janssen Pharmaceuticals, Inc ($114,743) |
All Payment Transactions
1,818 individual payment records from CMS Open Payments — Page 1 of 73
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $23.76 | General |
| 12/12/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: DIABETES | ||||||
| 12/10/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $15.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: Cardio-renal | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.16 | General |
| Category: DIABETES | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: DIABETES | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: DIABETES | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,075.00 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: DIABETES | ||||||
| 11/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Cardiology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/05/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/29/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $105.94 | General |
| 10/29/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $29.55 | General |
| Category: Genetic Disease | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $116.52 | General |
| Category: DIABETES | ||||||
| 10/24/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 3,378 | 7,600 | $918,840 | $268,613 |
| 2022 | 20 | 3,057 | 4,301 | $837,999 | $248,694 |
| 2021 | 23 | 2,907 | 4,363 | $850,219 | $259,335 |
| 2020 | 23 | 3,050 | 4,451 | $880,285 | $248,079 |
Total Patients
12,392
Total Services
20,715
Medicare Billing
$1.0M
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 770 | 1,313 | $270,694 | $109,250 | 40.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 420 | 437 | $246,931 | $56,474 | 22.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 90 | 209 | $35,948 | $18,815 | 52.3% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 111 | 112 | $61,600 | $16,992 | 27.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 79 | 201 | $24,168 | $12,169 | 50.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 673 | 1,039 | $56,106 | $9,808 | 17.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 68 | 68 | $15,621 | $6,412 | 41.0% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2023 | 28 | 28 | $21,700 | $5,637 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $13,800 | $5,491 | 39.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 96 | 99 | $14,256 | $5,136 | 36.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 86 | 87 | $73,776 | $4,877 | 6.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 453 | 510 | $10,710 | $2,983 | 27.8% |
| 75571 | Ct scan of heart with evaluation of blood vessel calcium | Office | 2023 | 45 | 45 | $5,895 | $2,967 | 50.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 60 | 60 | $15,000 | $2,294 | 15.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 25 | 78 | $11,700 | $1,587 | 13.6% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 38 | 107 | $16,050 | $1,472 | 9.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 19 | $2,660 | $1,244 | 46.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 86 | 87 | $3,219 | $895.64 | 27.8% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 13 | 29 | $5,800 | $668.40 | 11.5% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 14 | 35 | $2,100 | $581.83 | 27.7% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 12 | 15 | $2,025 | $577.37 | 28.5% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 11 | 21 | $1,281 | $549.15 | 42.9% |
| 93017 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) | Office | 2023 | 21 | 21 | $2,436 | $438.34 | 18.0% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 35 | 2,855 | $485.35 | $339.72 | 70.0% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 21 | 21 | $945.00 | $335.58 | 35.5% |
About Dr. Denzil Moraes, M.D
Dr. Denzil Moraes, M.D is a Cardiovascular Disease healthcare provider based in Baton Rouge, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952381980.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Denzil Moraes, M.D has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $93,548 received in 2024. These payments were reported across 1,818 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Moraes has provided services to 12,392 Medicare beneficiaries, totaling 20,715 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Baton Rouge, LA
- Active Since 01/17/2006
- Last Updated 04/28/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1952381980
Products in Payments
- XARELTO (Drug) $491,098
- JARDIANCE (Drug) $393,757
- NEXLIZET (Drug) $186,609
- ENTRESTO (Drug) $172,322
- NEXLETOL (Drug) $13,469
- LifeVest (Device) $1,011
- UPTRAVI (Drug) $875.96
- Repatha (Biological) $838.26
- Corlanor (Drug) $583.21
- Resolute (Device) $516.30
- BRILINTA (Drug) $441.71
- Kerendia (Drug) $426.09
- RESOLUTE ONYX (Device) $419.09
- LEQVIO (Drug) $380.88
- Impella (Device) $355.59
- VERQUVO (Drug) $341.69
- ELIQUIS (Drug) $325.93
- OPSUMIT (Drug) $297.80
- Vascepa (Drug) $294.71
- FARXIGA (Drug) $253.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Baton Rouge
George Karam, Md, MD
Cardiovascular Disease — Payments: $321,210
Cardiovascular Disease $321,210
David Moll, Md, MD
Cardiovascular Disease — Payments: $128,748
Cardiovascular Disease $128,748
Mark Pollet, Md, MD
Cardiovascular Disease — Payments: $116,274
Cardiovascular Disease $116,274
Dr. Tara Jarreau, M.d, M.D
Cardiovascular Disease — Payments: $111,344
Cardiovascular Disease $111,344
Venkata Satish Gadi, M.d, M.D
Cardiovascular Disease — Payments: $105,858
Cardiovascular Disease $105,858
Steven Kelley, Md, MD
Cardiovascular Disease — Payments: $82,130
Cardiovascular Disease $82,130